Into the twilight zone – should ER-low breast cancer be treated as triple negative breast cancer?
Jernström, Helena LU and Rydén, Lisa LU
(2024)
In The Lancet Regional Health - Europe
40.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/c51ff152-1d39-45b9-ae87-7a61f3c0029e
- author
- Jernström, Helena
LU
and Rydén, Lisa
LU
- organization
-
- EpiHealth: Epidemiology for Health
- Cancerepidemiology and radiation
- LUCC: Lund University Cancer Centre
- Epidemiology and pharmacogenetics (research group)
- Breast cancer treatment
- The Liquid Biopsy and Tumor Progression in Breast Cancer (research group)
- Breast Cancer Surgery (research group)
- Surgery (Lund)
- publishing date
- 2024-05
- type
- Contribution to journal
- publication status
- published
- subject
- in
- The Lancet Regional Health - Europe
- volume
- 40
- article number
- 100896
- publisher
- Elsevier
- external identifiers
-
- pmid:38590941
- scopus:85189450399
- ISSN
- 2666-7762
- DOI
- 10.1016/j.lanepe.2024.100896
- language
- English
- LU publication?
- yes
- id
- c51ff152-1d39-45b9-ae87-7a61f3c0029e
- date added to LUP
- 2024-04-23 15:07:49
- date last changed
- 2024-06-18 20:11:04
@misc{c51ff152-1d39-45b9-ae87-7a61f3c0029e,
author = {{Jernström, Helena and Rydén, Lisa}},
issn = {{2666-7762}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{The Lancet Regional Health - Europe}},
title = {{Into the twilight zone – should ER-low breast cancer be treated as triple negative breast cancer?}},
url = {{http://dx.doi.org/10.1016/j.lanepe.2024.100896}},
doi = {{10.1016/j.lanepe.2024.100896}},
volume = {{40}},
year = {{2024}},
}